Acidogenicity of buccal plaque after a single rinse with amine fluoride - stannous fluoride mouthrinse solution.
Caries and gingivitis prevention may benefit from chemotherapeutic plaque control, therefore we compared in a cross-over study with 5 subjects the anti-acidogenic effects of a single use of AmF-SnF2 mouthrinse solutions (Meridol with and without 5% alcohol) with baseline and with the effects of a placebo and a chlorhexidine mouthrinse (CHX). Buccal plaque was collected 0.5, 3 and 8 h after the subjects used one of the mouthrinses, each time before and after a rinse with 10% sucrose to induce lactic acid production. Samples were analysed for acid anions by capillary electrophoresis and for protein. At 0.5 h after the use of AmF-SnF2 or CHX, the concentration of acetate in resting plaque was 70% lower than at baseline or after using the placebo. Average post-sucrose acetate and lactate concentrations in the placebo group were 30-80% higher than at baseline; up to 3 h this difference was significant. 8 h after using AmF-SnF2 or CHX, the post-sucrose acetate and lactate concentrations were still 30-50% lower than after the placebo, and up to 40% lower than at baseline. To conclude, AmF-SnF2 in both Meridol formulations and CHX were shown to have a similar potency to inhibit acid production after a single rinse.
Damen
J J M
JJ
Department of Cariology Endodontology Pedodontology, Academic Centre for Dentistry Amsterdam (ACTA), The Netherlands.
Buijs
M J
MJ
ten Cate
J M
JM
D000085:Acetates / Q000032:analysis / Q000037:antagonists & inhibitors; D000328:Adult; D000588:Amines / Q000008:administration & dosage / Q000627:therapeutic use*; D000704:Analysis of Variance; D000891:Anti-Infective Agents, Local / Q000008:administration & dosage / Q000627:therapeutic use; D002264:Carboxylic Acids / Q000032:analysis; D002326:Cariogenic Agents / Q000494:pharmacology; D002327:Cariostatic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002710:Chlorhexidine / Q000008:administration & dosage / Q000627:therapeutic use; D018592:Cross-Over Studies; D003773:Dental Plaque / Q000378:metabolism* / Q000517:prevention & control; D004338:Drug Combinations; D004586:Electrophoresis; D000431:Ethanol; D006801:Humans; D007773:Lactates / Q000032:analysis / Q000037:antagonists & inhibitors; D008297:Male; D008875:Middle Aged; D009067:Mouthwashes / Q000627:therapeutic use*; D014677:Pharmaceutical Vehicles; D010919:Placebos; D011506:Proteins / Q000032:analysis; D013223:Statistics as Topic; D013395:Sucrose / Q000494:pharmacology; D013997:Time Factors; D014002:Tin Fluorides / Q000008:administration & dosage / Q000627:therapeutic use*
D000085:Acetates; D000588:Amines; D000891:Anti-Infective Agents, Local; D002264:Carboxylic Acids; D002326:Cariogenic Agents; D002327:Cariostatic Agents; D004338:Drug Combinations; D007773:Lactates; D009067:Mouthwashes; D014677:Pharmaceutical Vehicles; D010919:Placebos; D011506:Proteins; D014002:Tin Fluorides; C059813:Meridol; D000431:Ethanol; D013395:Sucrose; D002710:Chlorhexidine